JP2023518038A - 改変されたアンジオテンシン変換酵素２（ａｃｅ２）またはその使用 - Google Patents

改変されたアンジオテンシン変換酵素２（ａｃｅ２）またはその使用 Download PDF

Info

Publication number
JP2023518038A
JP2023518038A JP2022555643A JP2022555643A JP2023518038A JP 2023518038 A JP2023518038 A JP 2023518038A JP 2022555643 A JP2022555643 A JP 2022555643A JP 2022555643 A JP2022555643 A JP 2022555643A JP 2023518038 A JP2023518038 A JP 2023518038A
Authority
JP
Japan
Prior art keywords
ace2
cov
amino acid
sace2
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022555643A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518038A5 (https=
Inventor
エリック プロッコ，
アスラー マリック，
ジャリーズ レーマン，
リャンフイ ジャン，
シーチン ション，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois System
Original Assignee
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Illinois System filed Critical University of Illinois System
Publication of JP2023518038A publication Critical patent/JP2023518038A/ja
Publication of JP2023518038A5 publication Critical patent/JP2023518038A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
JP2022555643A 2020-03-16 2021-03-16 改変されたアンジオテンシン変換酵素２（ａｃｅ２）またはその使用 Pending JP2023518038A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202062989976P 2020-03-16 2020-03-16
US62/989,976 2020-03-16
US202063022151P 2020-05-08 2020-05-08
US63/022,151 2020-05-08
US202063042907P 2020-06-23 2020-06-23
US63/042,907 2020-06-23
US202063089895P 2020-10-09 2020-10-09
US63/089,895 2020-10-09
PCT/US2021/022611 WO2021188576A1 (en) 2020-03-16 2021-03-16 Modified angiotensin-converting enzyme 2 (ace2) and use thereof

Publications (2)

Publication Number Publication Date
JP2023518038A true JP2023518038A (ja) 2023-04-27
JP2023518038A5 JP2023518038A5 (https=) 2024-02-29

Family

ID=75439530

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022555643A Pending JP2023518038A (ja) 2020-03-16 2021-03-16 改変されたアンジオテンシン変換酵素２（ａｃｅ２）またはその使用

Country Status (8)

Country Link
US (1) US20230193235A1 (https=)
EP (1) EP4121170A1 (https=)
JP (1) JP2023518038A (https=)
KR (1) KR20220154796A (https=)
AU (1) AU2021239879A1 (https=)
BR (1) BR112022018527A2 (https=)
CA (1) CA3174683A1 (https=)
WO (1) WO2021188576A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116057176A (zh) * 2020-03-21 2023-05-02 赖瑞克斯生物科技公司 Ace2和补体途径的双特异性和三特异性功能分子及其用途
EP3884957A1 (en) * 2020-03-26 2021-09-29 The University of British Columbia Methods for treatment of virus and methods for screening of anti-virus reagent using organoids
US20230257726A1 (en) * 2020-05-11 2023-08-17 Chan Zuckerberg Biohub, Inc. Ace2 compositions and methods
IL276627A (en) * 2020-08-10 2022-03-01 Yeda Res & Dev Compositions for diagnosis and treatment of coronavirus infections
CN117120621A (zh) * 2020-11-12 2023-11-24 上海科技大学 提高效率和准确性的基因组编辑
JP2024540722A (ja) * 2021-11-01 2024-11-01 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 変異型アンジオテンシン変換酵素２（ａｃｅ２）を含む組換え／融合ポリペプチド
WO2023081958A1 (en) * 2021-11-11 2023-05-19 The Macfarlane Burnet Institute For Medical Research And Public Health Ltd Antiviral agent comprising a cellular entry receptor and fc region component
CN114606219B (zh) * 2022-04-01 2023-10-31 北京大学 一种冠状病毒中和效应蛋白及其应用
EP4507787A1 (en) * 2022-04-13 2025-02-19 Paradigm Immunotherapeutics, Inc. Methods of preventing or treating infection by respiratory viruses including sars-cov-2
CN117304317B (zh) * 2022-06-28 2024-08-02 四川大学 Ace2受体特异性结合肽及其应用
EP4386084A1 (en) * 2022-12-14 2024-06-19 Formycon AG Improved ace2 fusion proteins
WO2024215776A1 (en) * 2023-04-10 2024-10-17 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Recombinant ace2 polypeptide and uses thereof
KR20240177843A (ko) * 2023-06-20 2024-12-30 주식회사 엔큐라젠 SARS-CoV-2스파이크 단백질에 특이적으로 결합하는 펩타이드 및 이의 용도
CN117447609A (zh) * 2023-10-25 2024-01-26 山西锦波生物医药股份有限公司 灭活冠状病毒的融合蛋白及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1515752E (pt) * 2002-06-19 2009-03-05 Univ Health Network Activação de ace2 para o tratamento de doença cardíaca, pulmonar e renal e de hipertensão
AU2013216910A1 (en) * 2012-02-10 2014-08-28 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of peripheral vascular disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIORXIV PREPRINT DOI: HTTPS://DOI.ORG/10.1101/2020.02.01.929976, JPN6025009494, February 2020 (2020-02-01), ISSN: 0005544084 *
エッセンシャル タンパク質工学, JPN6025009496, 2018, pages 156 - 157, ISSN: 0005544085 *

Also Published As

Publication number Publication date
EP4121170A1 (en) 2023-01-25
AU2021239879A1 (en) 2022-09-29
WO2021188576A1 (en) 2021-09-23
US20230193235A1 (en) 2023-06-22
CA3174683A1 (en) 2021-09-23
KR20220154796A (ko) 2022-11-22
BR112022018527A2 (pt) 2022-10-25

Similar Documents

Publication Publication Date Title
JP2023518038A (ja) 改変されたアンジオテンシン変換酵素２（ａｃｅ２）またはその使用
Procko The sequence of human ACE2 is suboptimal for binding the S spike protein of SARS coronavirus 2
Zhang et al. Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy
US20230257726A1 (en) Ace2 compositions and methods
US11466062B2 (en) Ankyrin repeat binding proteins and their uses
CN111961133A (zh) 一种针对新冠病毒SARS-CoV-2棘突蛋白非RBD区的单克隆抗体及其应用
JP7554837B2 (ja) 可溶性ａｃｅ２及び融合タンパク質、並びにその適用
York et al. A novel zinc-binding domain is essential for formation of the functional Junin virus envelope glycoprotein complex
WO2022058591A2 (en) Sars-cov-2-nanobodies
US20100261640A1 (en) Soluble and membrane anchored forms of lassa virus subunit proteins
CN119998313A (zh) 沙贝病毒刺突蛋白s2亚基结合剂
US20240398911A1 (en) Engineered receptors and monoclonal antibodies for cronaviruses and uses thereof
Dahal et al. Peptides and peptidomimetics as therapeutic agents for Covid‐19
De Cae et al. Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that clamp the spike at its base
US20240117012A1 (en) Anti-sars-cov-2 antibody
Pöhlmann et al. Interaction between the spike protein of human coronavirus NL63 and its cellular receptor ACE2
CN114891075A (zh) 一种对新冠病毒s蛋白rbmfp结构域具有结合亲和力的多肽及其应用
US20170198014A1 (en) Polypeptides and their use for treating influenza
EA048858B1 (ru) Модифицированный ангиотензинпревращающий фермент 2 и его применение
CN116601291A (zh) 修饰的血管紧张素转换酶2（ace2）及其用途
RU2837537C1 (ru) Растворимый апф2, его слитый белок и способы их применения
US20250145692A1 (en) Chimera molecules for sars-cov-2 and methods of use
Werner Identification of lead molecules for the development of antivirals targeting the Ebola virus matrix protein VP40
WO2025090946A1 (en) Compositions and methods for treating or preventing viral infection or for making a cell susceptible to viral infection or cell fusion
von Beck Discovery of SARS-CoV-2 Antivirals from Zoonotic Peptides and Repurposed Drugs

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250606

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251205